This suggests that monitoring these peripheral blood markers before treatment could aid in predicting the likelihood of irAEs in advanced NSCLC patients undergoing PD-1/PD-L1 inhibitor therapy. Here, PDCD1 is linked to non-small cell lung carcinoma.